Six years ago, what is now Canamedics started as a family project. Based in Barcelona, the team initially focused on research - three years spent testing different strains, production methods, and cultivation environments. Over time, the results led to the development of a specific indoor production system and a set of strains that caught the attention of distributors in Germany. A letter of intent followed, signed specifically for those flowers. "That marked the transition: from a small family effort to an industrial-scale facility, built with the goal of achieving full compliance and certification for pharmaceutical-grade exports," says Luis Comas Gomez, CEO of Canamedics.
© Canamedics
A long journey
The team is cautiously optimistic about timelines. They have recently undergone the final inspection by the Spanish Agency of Medicines and Medical Devices to obtain EU-GMP certification, having completed the required pharmaceutical validation batches during 2024. They expect to receive certification by September. If that happens, they're ready. "A signed binding term sheet with a German distributor will trigger a three-year partnership, with the first production batches scheduled for delivery in March or April 2026. From then on, every batch will be directed to that distributor," he adds.
According to Luis, Canamedics is the first indoor cannabis production site in Spain. "In a European market where most indoor products are still imported from Canada, we represent a local alternative." While many companies started with greenhouse cultivation, Canamedics committed early on to small-batch indoor growing. "That choice stems from a focus on consistency and the long-term goal of avoiding irradiation - a method often used to comply with microbial limits, but one we don't want to use."
© Canamedics
The issue of consistency is not abstract. Patients dealing with chronic conditions rely on stable treatments. When a flower that works well suddenly disappears from the market, or reappears with different effects, it undermines both the trust and the therapeutic potential of the product. "Our goal is not to chase volume or branding, but to establish transparent relationships with distributors, doctors, and patients, making clear who is behind the product, and how it's grown."
Premium is a word often used, but rarely defined. "At Canamedics, quality is measured on two fronts," Luis points out. "First, regulatory compliance: meeting EU-GMP standards, including THC concentration, microbial counts, heavy metals, and pest control. But we don't stop at the ±10% tolerance allowed by pharmacopeia specifications. We aim for a tighter ±5% variation in active ingredient content. For the first product we plan to release, that level of consistency has already been achieved. Cultivation choices reflect that: plant heights are maintained between 40 and 50 cm to ensure uniformity between top and bottom flowers."
On top of, Canamedics is working to bring objectivity to aspects often considered subjective - aroma, flavor, bud structure, trichome quality. "Every element is studied, from the way the flower smells when the jar is first opened to the coloration and terpene combinations that shape the experience. The process is as manual as possible, with automation introduced only when it doesn't compromise product character."
A researched approach
The path to this production model involved exhaustive testing. Greenhouse setups were explored and abandoned in favor of indoor systems that offered better consistency. More than a dozen strains were grown under different conditions. Rock wool emerged as the substrate of choice, despite its unforgiving nature - because it enabled standardization, Luis says. Lighting systems evolved too. Originally HPS, then switching to LEDs as technology advanced, offering spectrum flexibility and reduced energy consumption. Various approaches and controlled conditions for drying, trimming, curing, and packaging were tested.
© Canamedics
Cultivation rooms are limited in size - no larger than 100–120 m², with around 80–90 m² allocated to plants. The team tested vertical farming but decided to delay implementation, noting that the technology still needs time to mature for stable results. "Ceiling height in the facility is 7 meters, so that option remains on our table for later stages."
Cultivation matters but so does processing. After testing different methods and seeing their impact on final quality, the team designed a cold, laminar-flow hang-drying process, followed by semi-dry trimming using blade-free technology with manual finishing. The product is then gently cured in an automated system and heat-sealed under nitrogen.
Sanitation is handled with care. Low-concentration hydrogen peroxide generators - under 0.07 ppm - maintain air purity, reducing microbial presence without harming flowers. Almost all processes are automated, except for defoliation. "The plants are rather short, although increasing plant height is under consideration to improve yield per square meter."
Water systems are another area of focus. Canamedics is investing heavily in a fully automated, advanced irrigation system to match the level of control already present in the best indoor operations.
© Canamedics
Accessing MMJ
In Spain, current access to medicinal cannabis remains limited. Only a few approved medications like Sativex and Epidiolex are available through hospital channels. The recent legislative shift focuses on magistral preparations, but restricts access to four specific indications: spasticity, nausea and appetite loss related to chemotherapy, and HIV treatment side effects. These preparations will be based on extracts, with dried flower not permitted at this stage. Distribution will be limited to hospitals, excluding pharmacies. "While restrictive, we see this as a first step. The language of the regulation hints at future adaptation, recognizing that the broader healthcare system needs time to absorb the new framework."
© Canamedics
In the meantime, Canamedics prepares. Not only for certification, but for a future where natural products - grown locally, consistently, and transparently - can find their place within a system that has long been hesitant. "Our approach blends data with detail, research with respect for the plant, and a long-term vision rooted in patient need rather than market trends."
For more information:
Canamedics
Barcelona, Spain
info@canamedics.com
canamedics.com